✓ Independent editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Weight Loss · HGH Fragment

HGH Fragment 176-191

Released: Last reviewed:

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

HGH Fragment 176-191 is the same C-terminal sequence as AOD-9604, often sold under the unbranded name. Marketed for lipolysis; evidence for human weight loss is minimal.

HGH Fragment 176-191 at a glance

HGH Fragment 176-191 is the same C-terminal sequence as AOD-9604, often sold under the unbranded name. Marketed for lipolysis; evidence for human weight loss is minimal. Mechanism: HGH fragment (176-191). Typical route: Subcutaneous injection. FDA status: Not FDA-approved. Often dispensed by peptide-compounding pharmacies or sold as a 'research chemical' not intended for human consumption.

Drug classHGH fragment (176-191)
Half-life~30 minutes
RouteSubcutaneous injection
Research dosing250-500 mcg/day
FDA statusNot approved
Available throughSee the dated FDA status notice above

Mechanism of action

The peptide mimics the proposed lipolytic domain of human growth hormone, theoretically stimulating fat breakdown while avoiding GH's effects on glucose and IGF-1. In humans, demonstrated clinical effects on body composition have been modest and inconsistent.

Dosing reference

Research-protocol dosing: 250-500 mcg subcutaneously once or twice daily. Cycled 5 days on / 2 days off in some protocols. Not a clinically validated regimen.

Dosing information is provided for educational reference and is not medical advice. Patients should not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Often dispensed by peptide-compounding pharmacies or sold as a 'research chemical' not intended for human consumption.

Editor’s pick · NexLife · 94/100 (v4.1 methodology)

NexLife — compounded semaglutide

$95/month on a 12-month plan

$99 on 6 months · $105 on 3 months · $109 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).

Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.

Pharmacies named on its plan pages: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.

See NexLife’s current semaglutide plans → Read our NexLife review

Trade-offs: compounded semaglutide is not FDA-approved and is not Wegovy or Ozempic. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.
Editor’s pick · NexLife · 94/100 (v4.1 methodology)

NexLife — compounded tirzepatide

$115/month on a 12-month plan

$119 on 6 months · $125 on 3 months · $129 month to month. The same price at every dose and no membership fee (nexlife.us plan page, read November 6, 2026).

Included in the price: the medication, medical guidance from NexLife Medical Group, a GLP-1 nutrition plan, a 1:1 call with a certified wellness coach, 24/7 support and free expedited shipping. Lab work is not listed as included.

Pharmacies named on its plan pages: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA), described as state-licensed 503A compounding pharmacies.

See NexLife’s current tirzepatide plans → Read our NexLife review

Trade-offs: compounded tirzepatide is not FDA-approved and is not Zepbound or Mounjaro. Cash pay only (FSA/HSA cards accepted for eligible portions). Cancellations take effect after 30 days, so one more shipment may be charged. A prescription depends on a licensed clinician’s review.

U.S. telehealth providers that work with HGH Fragment 176-191

1
96/100May 2026 review (v3.0 rubric); v4.1 re-score pending

Offering and price for this peptide not verified in the October 15, 2026 update.

Read review →
–
88/100May 2026 review (v3.0 rubric); v4.1 re-score pending

Offering and price for this peptide not verified in the October 15, 2026 update.

Read review →
–
78/100May 2026 review (v3.0 rubric); v4.1 re-score pending

Offering and price for this peptide not verified in the October 15, 2026 update.

Read review →
–
76/100May 2026 review (v3.0 rubric); v4.1 re-score pending

Offering and price for this peptide not verified in the October 15, 2026 update.

Read review →
–
80/100May 2026 review (v3.0 rubric); v4.1 re-score pending

Offering and price for this peptide not verified in the October 15, 2026 update.

Read review →

Related weight loss / glp-1 peptides

Browse the full Weight Loss / GLP-1 category →

Frequently asked questions about HGH Fragment 176-191

Is HGH Fragment 176-191 the same as AOD-9604?

They cover the same amino-acid sequence. AOD-9604 was the branded research version. In practice, peptide compounding pharmacies sell either name with similar product specifications.

Should I use HGH Fragment 176-191 for weight loss?

There is limited clinical evidence supporting meaningful weight loss in humans. GLP-1 receptor agonists (semaglutide, tirzepatide) have far stronger evidence and FDA approval.

References

  1. Heffernan M, Summers RJ, Thorburn A, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Endocrinology. 2001;142(12):5182-5189. PMID: 11713213
  2. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000;53(6):274-278. PMID: 11146367

Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.